Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
RESEARCH TOOLSreports
Holding CRSP?
Track your performance easily
CRSP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.52 - $91.10
Previous CloseN/A
Volume437.82K
Average Volume (3M)1.83M
Market Cap
$3.27B
Enterprise Value$2.30B
Total Cash (Recent Filing)$315.52M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Feb 18, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding85,353,480
10 Day Avg. Volume1,805,419
30 Day Avg. Volume1,832,240
Standard Deviation0.19
R-Squared0.21
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.53
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue11.32
Enterprise Value/Gross Profit9.58
Enterprise Value/Ebitda-12.07
Forecast
1Y Price Target
$65.75Price Target Upside63.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Crispr Therapeutics AG News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCRISPR Therapeutics presented preliminary safety and efficacy data from the trial of their 2nd-gen allo CD19 CAR-T therapy CTX112 showing a 67% overall response rate and 50% complete response rate.
Financial PositionCRISPR Therapeutics maintains a strong cash position, which is advantageous in conditions of market uncertainty.
Regulatory Approvals And PartnershipsVertex recently negotiated a voluntary agreement with the Centers for Medicare & Medicaid Services, providing a single outcomes-based arrangement for Casgevy to ensure broad and equitable access.
Bears Say
Competitive LandscapeResponse rates for CTX112 in large B-cell lymphoma are below those reported for autologous CAR-T therapies like Yescarta and Breyanzi and other treatments in development.
Financial PerformanceRevenue recognition for Casgevy is taking longer than expected, leading to adjusted sales estimates.
Market SentimentCurrent investor sentiment towards gene editing is luke-warm, and near-term updates are not seen as key value inflection points.
---
Ownership Overview
1.66% Insiders
16.53% Mutual Funds
0.30% Other Institutional Investors
64.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $36.52 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Crispr Therapeutics AG’s market cap is $3.27B.
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Feb 18, 2025 which is in 31 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Nov 05, 2024. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.408 by $0.398.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -1.23.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 85,353,480 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.408. Following the earnings report the stock price went down -0.455%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 352M.
---
Crispr Therapeutics AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.75 (63.15% Upside)
$65.75 (63.15% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 113.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.46%
12-Months-Change
Fundamentals
Return on Equity
-13.07%
Trailing 12-Months
Asset Growth
8.11%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$65.75
▲(63.15% Upside)
Technical Analysis
Beam Therapeutics
―
Intellia Therapeutics
―
Editas Medicine
―
Sangamo Biosciences
―
Verve Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+17.36%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +17.36% per trade.
---